Lophora ApS

Lophora is a preclinical biotech company. The company has identified and patented a new class of proprietary compounds with a similar pharmacological profile to psilocybin, which has shown promising clinical results in treating a variety of conditions such as depression and addiction.

The company is currently bringing its first-in-class lead molecule LPH-5 through pre-clinical toxicological evaluation and expects to be ready for IND/CTA submission by the end of 2021, allowing for the initiation of clinical trials in early 2022.

Based on +10 years of research from the University of Copenhagen, Lophora was founded in 2018 with the ambition of developing a novel class of proprietary small molecules with a unique selectivity profile to address conditions with significant unmet need such as Treatment-Resistant Depression, whose patients remain largely underserved.

Contact name:

Bo Tandrup

Address:

BII, Ole Maaløesvej 3, 2200 Copenhagen N

Telephone:

+45 51 86 84 82

Established:

2018

Number of employees:

4

If you cannot find what you are looking for or if you have feedback to our website, please do not hesitate to contact dd@danskbiotek.dk or +45 5150 0560

Copyright 2021 Danskbiotek. All rights reserved.